Indian Pharmas See Big Advantage In Moving Acquisitions To India
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers that made U.S. and European acquisitions have discovered they can save as much as 40 percent in manufacturing costs by moving production to India. Piramal Healthcare became an example of that success when it moved the inhalation anesthetics acquired from Rhodia of the United Kingdom to its manufacturing facilities in India. The success has led Piramal to consider moving the products of its U.S. acquisition, Minrad International, to India. Dr. Reddy's is considering a similar production shift. (Click here for more